ReviewImmunologic research2002
Designing immunotoxins for cancer therapy.
Review in Immunologic research, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 33 citations in OpenAlex.
- Sacituzumab govitecan and trastuzumab deruxtecan: two new antibody-drug conjugates in the breast cancer treatment landscape.ESMO open · 2021Review
- Simulation and Stability Assessment of Anti-EpCAM Immunotoxin for Cancer Therapy.Advanced pharmaceutical bulletin · 2018Article
- Review
- SMI-Ribosome inactivating protein conjugates selectively inhibit tumor cell growth.Chemical communications (Cambridge, England) · 2017Article
- Article
- Design optimization and characterization of Her2/neu-targeted immunotoxins: comparative in vitro and in vivo efficacy studies.Oncogene · 2014Article
- A human recombinant autoantibody-based immunotoxin specific for the fetal acetylcholine receptor inhibits rhabdomyosarcoma growth in vitro and in a murine transplantation model.Journal of biomedicine & biotechnology · 2010Article
- Evasion of ribonuclease inhibitor as a determinant of ribonuclease cytotoxicity.Current pharmaceutical biotechnology · 2008Review
- Membrane destabilization by ricin.European biophysics journal : EBJ · 2004Article
- Interleukin-4-Pseudomonas exotoxin chimeric fusion protein for malignant glioma therapy.Journal of neuro-oncology · 2003Review
- Production of recombinant immunotherapeutics for anticancer treatment: the role of bioengineering.BioengineeredReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Immunotoxins are therapeutic agents with a high degree of specificity and unique mechanism of action. An immunotoxin is a chimeric protein consisting of a targeting moiety linked to a toxin. The targeting moiety selectively binds to a tumor cell and targets it for death via the attached toxin. Generally, immunotoxins are specifically potent against cancer cells in vitro and in animal models of human malignancies. However, immunotoxins can be limited clinically by immunogenicity, toxicity, and instability. In this review, we offer ways to overcome these limitations to create "ideal immunotoxins" for cancer therapy. These include producing single chain targeting/toxin fusion proteins of fully human origin that are extracellularly stable but once internalized, can be cleaved by intracellular proteases to free the toxin and facilitate its translocation to the cytosol.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.